Tue, Apr. 1, 8:28 AM
- A district judge has upheld the validity of a patent on Eli Lilly's (LLY) blockbuster Alimta lung-cancer drug, which generates sales of $2.6B a year.
- The decision will maintain the treatment's exclusivity until 2022, pending the outcome of any appeal.
- Companies on the losing side in the case include Teva (TEVA) and Fresenius Kabi (APCVZ). (PR)
Jan. 15, 2013, 6:08 AMLooking to offset a patent cliff that could cut sales by up to $2.75B this year, Pfizer (PFE) is among the companies reportedly interested in acquiring Agila Specialties, the injectable-medicines unit of India's Strides Arcolab. Novartis (NVS), Mylan (MYL) and Fresenius (APCVZ) have also been eyeing Agila, which produces cancer treatments and antibiotics, and could be valued at $2B. | Comment!
There are no StockTalks on this stock yet.
APCVZ vs. ETF Alternatives
Currently, there's no company description for APCVZ.
Country: United States
Other News & PR